JP2002509104A5 - - Google Patents

Download PDF

Info

Publication number
JP2002509104A5
JP2002509104A5 JP2000539837A JP2000539837A JP2002509104A5 JP 2002509104 A5 JP2002509104 A5 JP 2002509104A5 JP 2000539837 A JP2000539837 A JP 2000539837A JP 2000539837 A JP2000539837 A JP 2000539837A JP 2002509104 A5 JP2002509104 A5 JP 2002509104A5
Authority
JP
Japan
Prior art keywords
composition
magnesium
pills
memantine
dextromethorphan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000539837A
Other languages
English (en)
Japanese (ja)
Other versions
JP4562911B2 (ja
JP2002509104A (ja
Filing date
Publication date
Priority claimed from US09/006,641 external-priority patent/US5952389A/en
Priority claimed from US09/193,892 external-priority patent/US6294583B1/en
Priority claimed from US09/224,829 external-priority patent/US6057373A/en
Application filed filed Critical
Priority claimed from PCT/US1999/000144 external-priority patent/WO1999036064A2/en
Publication of JP2002509104A publication Critical patent/JP2002509104A/ja
Publication of JP2002509104A5 publication Critical patent/JP2002509104A5/ja
Application granted granted Critical
Publication of JP4562911B2 publication Critical patent/JP4562911B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000539837A 1998-01-13 1999-01-13 遅発性ジスキネジア及び他の運動障害の治療方法 Expired - Lifetime JP4562911B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/006,641 US5952389A (en) 1998-01-13 1998-01-13 Methods of treating tardive dyskinesia and other movement disorders
US09/006,641 1998-01-13
US09/193,892 1998-11-18
US09/193,892 US6294583B1 (en) 1998-01-13 1998-11-18 Methods of treating tardive dyskinesia and other movement disorders
US09/224,829 US6057373A (en) 1997-05-22 1999-01-04 Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US09/224,829 1999-01-04
PCT/US1999/000144 WO1999036064A2 (en) 1998-01-13 1999-01-13 Methods of treating tardive dyskinesia and other movement disorders

Publications (3)

Publication Number Publication Date
JP2002509104A JP2002509104A (ja) 2002-03-26
JP2002509104A5 true JP2002509104A5 (enExample) 2006-03-09
JP4562911B2 JP4562911B2 (ja) 2010-10-13

Family

ID=27358163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539837A Expired - Lifetime JP4562911B2 (ja) 1998-01-13 1999-01-13 遅発性ジスキネジア及び他の運動障害の治療方法

Country Status (6)

Country Link
EP (1) EP1047436B1 (enExample)
JP (1) JP4562911B2 (enExample)
CN (1) CN1293573A (enExample)
AU (1) AU765522B2 (enExample)
CA (1) CA2318095C (enExample)
WO (1) WO1999036064A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
AUPR625901A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method for treatment and/or prophylaxis
JP2005518411A (ja) * 2002-01-16 2005-06-23 エンド ファーマシューティカルズ インコーポレーテッド 中枢神経系の障害を治療する製薬組成物及び方法
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
CA2576232C (en) * 2004-05-14 2009-10-27 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
TW200626160A (en) * 2004-09-23 2006-08-01 Merz Pharma Gmbh & Co Kgaa Memantine for the treatment of childhood behavioral disorders
BRPI0518483A2 (pt) * 2004-11-23 2008-11-18 Neuromolecular Pharmaceuticals Inc composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
EA200800663A1 (ru) * 2005-09-16 2008-10-30 Сириусайенс Аб Способ и средство профилактики и лечения нарушенного дыхания во время сна
SG10201502642TA (en) 2006-10-12 2015-05-28 Bhi Ltd Partnership Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid
CN104379138B (zh) * 2011-12-02 2021-12-07 思康脑侒股份有限公司 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2914365C (en) * 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
PL3160464T3 (pl) * 2014-06-26 2018-12-31 Contera Pharma Aps 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
CN104188970A (zh) * 2014-08-26 2014-12-10 上海交通大学医学院附属新华医院 右美沙芬在治疗眼睑痉挛或梅杰综合征中的应用
CN108348518A (zh) * 2015-09-08 2018-07-31 费城儿童医院 诊断和治疗焦虑症的方法
BR112019015362A2 (pt) * 2017-02-10 2020-10-20 Asarina Pharma Ab 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico
CN111902138A (zh) * 2018-01-29 2020-11-06 法奈克斯公司 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗
CA3137407A1 (fr) 2019-05-16 2020-11-19 Synapharm Industrial Synthesis Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder
CN115184501A (zh) * 2022-07-20 2022-10-14 中国医学科学院病原生物学研究所 血清代谢物组合筛查在诊断肌张力障碍症中的应用
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4985256A (en) * 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5470978A (en) * 1992-11-18 1995-11-28 Eli Lilly And Company Process and intermediates for the preparation of excitatory amino acid receptor antagonists
WO1996007412A1 (en) * 1994-09-02 1996-03-14 Virginia Commonwealth University Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists

Similar Documents

Publication Publication Date Title
JP2002509104A5 (enExample)
Johnston et al. Action of the neurotoxin kainic acid on high affinity uptake of L‐glutamic acid in rat brain slices
EP0660707B1 (en) Amantadine and related compounds for use in the treatment of peripheral neuropathy
DE69733081T2 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US20030064122A1 (en) Abuse resistant pharmaceutical composition containing capsaicin
AP1665A (en) Tamper-resistant oral opioid agonist formulations.
JP2002539245A5 (enExample)
CA2318095A1 (en) Methods of treating tardive dyskinesia and other movement disorders
EP0252290A2 (en) Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
AU3357800A (en) Method of preparing alkylated salicylamides
UA88056C2 (uk) Дозована форма оксикодону, що вводиться один раз на день
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
SK14282000A3 (sk) Farmaceutický prostriedok na liečenie závislosti od alkoholu a drog obsahujúci opiátového antagonistu a modulátor súhrnu nmda receptorov
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
US20120064152A1 (en) Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same
UA76753C2 (uk) Комбінація галантаміну або дезоксипеганіну та протизбуджувального агента, її застосування (варіанти) для лікування наркотичної або токсичної залежності
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
RU99119233A (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
BR0013582A (pt) Agonistas retinóides seletivos para rar
BRPI0413883A (pt) composição e método para a administração de um composto farmacologicamente ativo a um mamìfero
CN103002893B (zh) 神经障碍性疼痛的治疗药或预防药
US3096241A (en) Synergistic antihistamine mixture
ATE425731T1 (de) Pharmazeutische zusammensetzungen eines nichtmagensaftresistenten protonenpumpen-hemmers mit einer carbonat- und bicarbonatsalzkombination